InfraScan, Inc. is a medical device company that focuses on developing, commercializing and distributing hand-held diagnostic devices for head injury and stroke based on near infrared (NIR) technologies.



The company has received early-stage funding from the Office of Naval Research, BioAdvance, the Biotechnology Greenhouse of Southeastern Pennsylvania, Ben Franklin Technology Partners of Southeastern Pennsylvania, and from the Philadelphia Industrial Development Corporation.



The Infrascanner brain hematoma detector is the first hand-held device of its kind designed to assist first responders and emergency room personnel in identifying life threatening brain hematomas, allowing expedient assessment of patients and potentially facilitating crucial treatment.



Intracranial hematomas resulting from a traumatic brain injury are life-threatening and patient outcomes can improve significantly if treated within an hour after an injury – known as the “golden hour”.



While most hospitals have a Computer Aided Tomography (CAT) scanner, which is viewed as the state-of-the-art technology for diagnosing a brain hematoma, many facilities lack the neurosurgical capabilities to treat the condition.



The early identification of a brain hematoma can play a significant role in facilitating transportation of critically injured patients to facilities, which can both verify Infrascanner’s early diagnosis and offer surgical intervention.



The Infrascanner is a small, completely portable device, which can detect the presence and location of a brain hematoma based on differential NIR light absorption of a hematoma and normal brain tissue. he science of diffused optical tomography used by the Infrascanner enables the conversion of light differential data into interpretative scientific results. The Infrascanner unit is a small, portable handheld device based on a PDA platform with wireless detector probes.